Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,292
datasets available to search
ShareScore release 0.9.0
Dataset results
5,292 results for “implants”
Post-implantation developmental defects induced by mtDNA mutation derive from altered DNA methylome in oocytes
GEO Series GSE147547. Mus musculus. 6 samples. Type: Methylation profiling by high throughput sequencing.
Gene expression profiles of subepithelial myofibroblasts from mouse ileum or colon, implanted together with human cancer cells in mouse xenografts
GEO Series GSE27564. Mus musculus; Homo sapiens. 12 samples. Type: Expression profiling by array.
Gene expression response to implanted drug (paclitaxel)-eluting or bare metal stents in denuded human LIMA arteries
GEO Series GSE19136. Homo sapiens. 12 samples. Type: Expression profiling by array.
LINE-1 retrotransposition impacts the genome of human pre-implantation embryos and extraembryonic tissues [twins]
GEO Series GSE149476. Homo sapiens. 8 samples. Type: Genome variation profiling by high throughput sequencing.
Exosomes from Hypoxia Preconditioned BMSCs Improve Peri-implant Osteogenesis under Type II Diabetes Condition via miR-106b-5p/HIF-1α Signaling Axis
GEO Series GSE275863. Rattus norvegicus. 6 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Modeling pre-implantation development using totipotent blastomere-like stem cells [Cut&tag]
GEO Series GSE243923. Mus musculus. 10 samples. Type: Other.
Data set from the article Lévesque V, Laplante L, Shohoudi A, Apers S, Kovacs AH, Luyckx K, Thomet C, Budts W, Enomoto J, Sluman MA, Lu CW, Jackson JL, Cook SC, Chidambarathanu S, Alday L, Eriksen K, Dellborg M, Berghammer M, Johansson B, Mackie AS, Menahem S, Caruana M, Veldtman G, Soufi A, Fernandes SM, White K, Callus E, Kutty S, Brouillette J, Casteigt B, Moons P, Khairy P; APPROACH-IS Consortium and the International Society for Adult Congenital Heart Disease (ISACHD). Implantable cardioverter-defibrillators and patient-reported outcomes in adults with congenital heart disease: An international study. Heart Rhythm. 2020 May;17(5 Pt A):768-776. doi: 10.1016/j.hrthm.2019.11.026. Epub 2019 Nov 30. PMID: 31790832.
<p>Data set from the article Lévesque V, Laplante L, Shohoudi A, Apers S, Kovacs AH, Luyckx K, Thomet C, Budts W, Enomoto J, Sluman MA, Lu CW, Jackson JL, Cook SC, Chidambarathanu S, Alday L, Eriksen K, Dellborg M, Berghammer M, Johansson B, Mackie AS, Menahem S, Caruana M, Veldtman G, Soufi A, Fernandes SM, White K, Callus E, Kutty S, Brouillette J, Casteigt B, Moons P, Khairy P; APPROACH-IS Consortium and the International Society for Adult Congenital Heart Disease (ISACHD). Implantable cardioverter-defibrillators and patient-reported outcomes in adults with congenital heart disease: An international study. Heart Rhythm. 2020 May;17(5 Pt A):768-776. doi: 10.1016/j.hrthm.2019.11.026. Epub 2019 Nov 30. PMID: 31790832.</p> <p> </p> <p>This is the abstract:</p> <p><strong>Background: </strong>Implantable cardioverter-defibrillators (ICDs) are increasingly being used to prevent sudden death in the growing population of adults with congenital heart disease (CHD). However, little is known about their impact on patient-reported outcomes (PROs).</p> <p><strong>Objective: </strong>The purpose of this study was to assess and compare PROs in adults with CHD with and without ICDs.</p> <p><strong>Methods: </strong>A propensity-based matching weight analysis was conducted to evaluate PROs in an international cross-sectional study of adults with CHD from 15 countries across 5 continents.</p> <p><strong>Results: </strong>A total of 3188 patients were included: 107 with ICDs and 3081 weight-matched controls without ICDs. ICD recipients were an average age of 40.1 ± 12.4 years, and >95% had moderate or complex CHD. Defibrillators were implanted for primary and secondary prevention in 38.3% and 61.7%, respectively. Perceived health status, psychological distress, sense of coherence, and health behaviors did not differ significantly among patients with and without ICDs. However, ICD recipients had a more threatening view of their illness (relative % difference 8.56; P = .011). Those with secondary compared to primary prevention indications had a significantly lower quality-of-life score (Linear Analogue Scale 72.0 ± 23.1 vs 79.2 ± 13.0; P = .047). Marked geographic variations were observed. Overall sense of well-being, assessed by a summary score that combines various PROs, was significantly lower in ICD recipients (vs controls) from Switzerland, Argentina, Taiwan, and the United States.</p> <p><strong>Conclusion: </strong>In an international cohort of adults with CHD, ICDs were associated with a more threatening illness perception, with a lower quality of life in those with secondary compared to primary prevention indications. However, marked geographic variability in PROs was observed.</p> <p> </p>
Candidacy and long-term outcomes of subcutaneous implantable cardioverter-defibrillators in current practice in patients with Hypertrophic Cardiomyopathy
<p>Dataset associated with paper "Candidacy and long-term outcomes of subcutaneous implantable cardioverter-defibrillators in current practice in patients with Hypertrophic Cardiomyopathy"</p> <p><strong>This set of raw data is accessible under request because include sensitive information. Please write your request at l.crotti@auxologico.it</strong></p>
Computer-based prediction of coronary artery compression in the planning of transcatheter pulmonary valve implantation.
<p>Datset from Pluchinotta FR, Caimi A, Pilati M, Carminati M, Sturla F. Computer-based prediction of coronary artery compression in the planning of transcatheter pulmonary valve implantation. EuroIntervention. 2021 Sep 20;17(7):584-585. doi: 10.4244/EIJ-D-20-01114. PMID: 33433388.</p> <p> </p>
Dataset related to the article "CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: an international Registry"
<p>This record contains raw data related to the article “CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: an international Registry” <br> </p> <p>Abstract</p> <p><strong>Aims: </strong>The aim of this registry was to evaluate the additional prognostic value of a composite cardiac magnetic resonance (CMR)-based risk score over standard-of-care (SOC) evaluation in a large cohort of consecutive unselected non-ischaemic cardiomyopathy (NICM) patients.</p> <p><strong>Methods and results: </strong>In the DERIVATE registry (www.clinicaltrials.gov/registration: RCT<a href="http://clinicaltrials.gov/show/NCT03352648">#NCT03352648</a>), 1000 (derivation cohort) and 508 (validation cohort) NICM patients with chronic heart failure (HF) and left ventricular ejection fraction <50% were included. All-cause mortality and major adverse arrhythmic cardiac events (MAACE) were the primary and secondary endpoints, respectively. During a median follow-up of 959 days, all-cause mortality and MAACE occurred in 72 (7%) and 93 (9%) patients, respectively. Age and >3 segments with midwall fibrosis on late gadolinium enhancement (LGE) were the only independent predictors of all-cause mortality (HR: 1.036, 95% CI: 1.0117-1.056, P < 0.001 and HR: 2.077, 95% CI: 1.211-3.562, P = 0.008, respectively). For MAACE, the independent predictors were male gender, left ventricular end-diastolic volume index by CMR (CMR-LVEDVi), and >3 segments with midwall fibrosis on LGE (HR: 2.131, 95% CI: 1.231-3.690, P = 0.007; HR: 3.161, 95% CI: 1.750-5.709, P < 0.001; and HR: 1.693, 95% CI: 1.084-2.644, P = 0.021, respectively). A composite clinical and CMR-based risk score provided a net reclassification improvement of 63.7% (P < 0.001) for MAACE occurrence when added to the model based on SOC evaluation. These findings were confirmed in the validation cohort.</p> <p><strong>Conclusion: </strong>In a large multicentre, multivendor cohort registry reflecting daily clinical practice in NICM work-up, a composite clinical and CMR-based risk score provides incremental prognostic value beyond SOC evaluation, which may have impact on the indication of implantable cardioverter-defibrillator implantation.</p>
Dataset related to the article "Leadless pacemaker implant, anticoagulation status, and outcomes: Results from the Micra Transcatheter Pacing System Post-Approval Registry"
<p>This record contains raw data related to the article "Leadless pacemaker implant, anticoagulation status, and outcomes: Results from the Micra Transcatheter Pacing System Post-Approval Registry". </p> <p> </p> <p><strong>Abstract</strong></p> <p><strong>Background: </strong>Early results from the Micra investigational trial and Micra Post-Approval Registry (PAR) demonstrated excellent safety and device performance; however, outcomes based on anticoagulation (AC) status at implant have not been evaluated.</p> <p><strong>Objective: </strong>The purpose of this study was to report implant characteristics, perforation rate, and vascular-related events based on perioperative oral AC strategy in patients undergoing Micra implant.</p> <p><strong>Methods: </strong>We compared procedure characteristics, major complications, and vascular events, including pericardial effusion, stratified by any adverse event (including major complications, minor complications, and observations) or major complication only according to AC status in the Micra PAR.</p> <p><strong>Results: </strong>Among 1795 patients with AC status available, 585 were not on AC, 795 had AC interrupted, and 415 had AC continued during Micra implant. Non-AC patients tended to be younger, with less history of atrial fibrillation and chronic obstructive pulmonary disease, and more history of dialysis than interrupted and continued patients. The implant success rate was similar for all groups (99.1%-99.8%). Through 30 days postimplant, the overall major complication rate was 3.1% for the non-AC group, 2.6% for the interrupted group, and 1.5% for the continued group. The combined rate for any vascular or pericardial effusion adverse event did not differ significantly among AC strategies (6.5%, 4.8%, and 3.6%, respectively).</p> <p><strong>Conclusion: </strong>Implant of Micra seems to be safe and feasible regardless of an interrupted or continued periprocedural oral AC strategy, with no increased risk of perforation or vascular complications.</p> <p><strong>Trial registration: </strong>ClinicalTrials.gov <a href="http://clinicaltrials.gov/show/NCT02536118">NCT02536118</a>.</p>
Dataset related to the article "Computed tomography predictors of structural valve degeneration in patients undergoing transcatheter aortic valve implantation with balloon-expandable prostheses"
<p>This record contains raw data related to the article "Computed tomography predictors of structural valve degeneration in patients undergoing transcatheter aortic valve implantation with balloon-expandable prostheses"</p> <p><strong>Objectives: </strong>Computed tomography (CT) provides excellent anatomy assessment of the aortic annulus (AoA) and is utilized for pre-procedural planning of transcatheter aortic valve implantation (TAVI). We sought to investigate if geometrical characteristics of the AoA determined by CT may represent predictors of structural valve degeneration (SVD) in patients undergoing TAVI with balloon-expandable valves.</p> <p><strong>Methods: </strong>Retrospective study on 124 consecutive patients (mean age:79±7 years; female: 61%) undergoing balloon-expandable TAVI prospectively enrolled in a registry<strong>. </strong>AoA maximum diameter (D<sub>max</sub>), minimum diameter (D<sub>min</sub>), and area were assessed using pre-procedural CT. SVD was identified during follow-up with transthoracic echocardiography documenting structural prosthetic valve abnormalities with or without hemodynamic changes. </p> <p><strong>Results: </strong>The mean follow up was 5.9±1.7 years. SVD was found in 48 out of 124 patients (38%). AoA D<sub>max</sub>, D<sub>min</sub> and area were significantly smaller in patients with SVD compared to patients without SVD (25.6±2.2 mm vs. 27.1±2.8 mm , p=0.012; 20.5±2.1 mm vs. 21.8±2.1 mm ,p=0.001 and 419±77 mm<sup>2 </sup>vs. 467±88 mm<sup>2</sup>,p=0.002, respectively). At univariable analysis, female sex, BSA, 23-mm prosthetic valve size, D<sub>max</sub> <27.1 mm and a D<sub>min</sub> < 19.9 mm were associated with SVD whereas at multivariable analysis, only D<sub>min</sub> <19.9 mm (OR=2.873, 95% CI: 1.191-6.929,p=0.019) and female sex (OR=2.659, 95% CI: 1.095-6.458, p=0.031) were independent predictors of SVD.</p> <p><strong>Conclusions: </strong>Female sex and AoA D<sub>min</sub> < 19.9 mm are associated with SVD in patients undergoing TAVI with balloon expandable valves. When implanting large prostheses in order to avoid paraprosthetic regurgitation, caution should be observed due to the risk of excessive stretching of the AoA D<sub>min,</sub> which may play a role in SVD.</p>
DataSet_Simultaneous versus staged approach in transcatheter aortic valve implantation for severe stenosis and endovascular aortic repair for thoracic and abdominal aortic aneurysm
Open the record for dataset details and reuse information.
Impact of aortic angle on transcatheter aortic valve implantation outcome with Evolut-R, Portico, and Acurate-NEO
<p>Dataset from Gorla R, De Marco F, Garatti A, Bianchi G, Popolo Rubbio A, Acerbi E, Casenghi M, Spagnolo P, Brambilla N, Testa L, Agnifili ML, Tusa M, Bedogni F. Impact of aortic angle on transcatheter aortic valve implantation outcome with Evolut-R, Portico, and Acurate-NEO. Catheter Cardiovasc Interv. 2021 Jan 1;97(1):E135-E145. doi: 10.1002/ccd.28957. Epub 2020 May 13. PMID: 32400068.</p> <p><strong>Abstract</strong></p> <p><strong>Objectives: </strong>To investigate paravalvular leak (PVL) and devices success rates according to aortic angle (AA) in patients undergoing transcatheter aortic valve implantation (TAVI) with three new-generation self-expanding devices.</p> <p><strong>Background: </strong>The impact of aortic angle (AA) on TAVI device success and PVL rates is controversial.</p> <p><strong>Methods: </strong>This retrospective study included 392 patients submitted to TAVI for severe aortic stenosis with Portico, Evolut-R and Acurate-NEO, and available AA measurements at computed tomography (CT) angiography. AA was calculated from the implantation projection and was defined as the angle between the plane of aortic annulus and an ideal horizontal plane. Aorta was defined horizontal if AA>57° (75th percentile).</p> <p><strong>Results: </strong>In the horizontal group, the rates of moderate/severe PVL was higher in the Evolut-R group (20.8%), which was also characterized by a lower implant compared to that of Acurate-NEO, whereas device success was comparable among the three devices. AA was a significant predictor of moderate/severe PVLs (AUC 0.72, p = .002) only in the Evolut-R population. On multivariate analysis, calcium volume 850HU, bicuspid aortic valve, and implantation depth at the level of left coronary cusp were independent predictors of moderate/severe PVL. On univariate analysis in the horizontal aorta population, implantation depth was confirmed among the most significant predictors of moderate/severe PVL.</p> <p><strong>Conclusions: </strong>Despite comparable device success rates, horizontal aorta represented a technical challenge only in the Evolut-R subgroup, which showed higher rates of moderate/severe PVL than Portico and Acurate-NEO, and was associated with a low implant.</p>
One-year safety and efficacy profile of transcatheter aortic valve-in-valve implantation with the portico system
<p>Dataset from Casenghi M, Gorla R, Popolo Rubbio A, De Marco F, Brambilla N, Agnifili M, Testa L, Bedogni F. One-year safety and efficacy profile of transcatheter aortic valve-in-valve implantation with the portico system. Catheter Cardiovasc Interv. 2021 Jul 1;98(1):E145-E152. doi: 10.1002/ccd.29353. Epub 2020 Nov 6. PMID: 33155757.</p> <p>Abstract</p> <p><strong>Objective: </strong>This study sought to investigate the procedural and mid-term outcomes of transcatheter aortic valve implantation for failed surgical bioprostheses (TAVI-ViV) with Portico device.</p> <p><strong>Background: </strong>Limited evidence coming from early experience on Portico system does not allow to fully assess safety and efficacy of this device in this ViV patients.</p> <p><strong>Methods: </strong>From January 2016 up to June 2019, 56 consecutive patients undergoing TAVI-ViV with Portico were prospectively included in our institutional TAVI database.</p> <p><strong>Results: </strong>The prevalent mechanism of failure was stenosis (58.9%); true internal diameter (ID) was <21 mm in 71.4% of cases. Device success rate were 69.6% with 14 (25%) patients showing a residual gradient ≥20 mmHg, 2 (3.6%) a PVL ≥ moderate and 1 (1.8%) required a second THV implantation due to device embolization. At 1-year follow-up 5 patients (8.9%) died whereas moderate SVD was reported in 2 (3.6%). Patients with a post-procedural mean gradient ≥20 mmHg showed a significantly higher rate of CV hospitalization (21.4% vs. 2.4%, p = .02) whereas no differences in procedural and 1-year outcomes were noticed according to true ID diameter or degeneration mode. Chimney stenting (ChT) was performed in 23 (41%) patients without significant differences in procedural and 1-year outcomes compared to non-ChT group.</p> <p><strong>Conclusions: </strong>TAVI-ViV with Portico valve was associated with good procedural and 1-year outcomes, even in patients with features of high procedural and anatomical complexity.</p>
Dataset related to the article "Cardiac magneticresonanceforprophylactic implantable-cardioverter defibrillator therapy international study:prognosticvalueofcardiac magnetic resonance-derivedrightventricular parameters substudy"
<p>This record contains partial raw data related to the article “Cardiac magneticresonanceforprophylactic implantable-cardioverter defibrillator therapy international study:prognosticvalueofcardiac magnetic resonance-derivedrightventricular parameters substudy"</p> <p><strong>Aims: </strong>Right ventricular (RV) systolic dysfunction (RVSD) has been recognized as an important determinant of outcomes in heart failure (HF) patients. However, assessment of RV volumes is challenging as the geometric complexity of the RV prohibits quantitative assessment by traditional 2D-echocardiography. Cardiac magnetic resonance (CMR) is the gold standard for RV chamber quantification with its high spatial resolution, precise definition of anatomy, and excellent reproducibility. In this study, we sought to investigate the incremental prognostic value of CMR-derived RV volumetric parameters in a large cohort of HF patients with reduced ejection fraction (HFrEF).</p> <p><strong>Methods and Results: </strong>Study cohort comprised of patients enrolled in the CarDiac MagnEtic Resonance for Primary Prevention Implantable CardioVerter DefibrillAtor ThErapy registry who had HFrEF and had simultaneous baseline CMR and echocardiography<br> (n=2449). RVSD was defined as RV ejection fraction (RVEF) <45%. Kaplan–Meier curves and cox regression were used to investigate the association between RVSD and all-cause mortality (ACM). Mean age was 59.8±14.0 years, 42.0% were female, and mean left ventricular ejection fraction (LVEF) was 34.0±10.8. Median follow-up was 959 days (interquartile range: 560–1590). RVSD was present in 936 (38.2%) and was an independent predictor of ACM (adjusted hazard ratio=1.44; 95%CI[1.09–1.91]; P=0.01). On subgroup analyses,the prognostic value of RVSD was more pronounced in NYHA I/II than in NYHAIII/IV, in LVEF <35% than in LVEF ≥35%, and in patients with renal dysfunction when compared to those with normal renal function.</p> <p><strong>Conclusions: </strong>RV dysfunction is an independent predictor of all-cause mortality in a large cohort of patients with HFrEF, with the prognostic value of RV dysfunction being more pronounced in select subgroups; likely reflecting the importance of RV function in the early stages of HF progression.</p>
Dataset related to the article "Cardiac Magnetic Resonance for Prophylactic Implantable-Cardioverter Defibrillator Therapy in Ischemic Cardiomyopathy The DERIVATE–ICM International Registry"
<p>This record contains raw data related to the article “Cardiac Magnetic Resonance for Prophylactic Implantable-Cardioverter Defibrillator Therapy in Ischemic Cardiomyopathy The DERIVATE–ICM International Registry”</p> <p><strong>BACKGROUND</strong> Implantable cardioverter-defibrillator (ICD) therapy is the most effective prophylactic strategy against sudden cardiac death (SCD) in patients with ischemic cardiomyopathy (ICM) and left ventricle ejection fraction (LVEF) #35% as detected by transthoracic echocardiograpgy (TTE). This approach has been recently questioned because of the low rate of ICD interventions in patients who received implantation and the not-negligible percentage of patients who experienced SCD despite not fulfilling criteria for implantation.</p> <p><strong>OBJECTIVES</strong> The DERIVATE (CarDiac MagnEtic Resonance for Primary Prevention Implantable CardioVerter DebrillAtor ThErapy)-ICM registry (NCT03352648) is an international, multicenter, and multivendor study to assess the net reclassification improvement (NRI) for the indication of ICD implantation by the use of cardiac magnetic resonance (CMR) as compared to TTE in patients with ICM.</p> <p><strong>METHODS</strong> A total of 861 patients with ICM (mean age 65 [1] 11 years, 86% male) with chronic heart failure and TTE-LVEF <50% participated. Major adverse arrhythmic cardiac events (MAACE) were the primary endpoints. RESULTS During a median follow-up of 1,054 days, MAACE occurred in 88 (10.2%). Left ventricular end-diastolic volume index (HR: 1.007 [95% CI: 1.000-1.011]; P ¼ 0.05), CMR-LVEF (HR: 0.972 [95% CI: 0.945-0.999]; P ¼ 0.045) and late gadolinium enhancement (LGE) mass (HR: 1.010 [95% CI: 1.002-1.018]; P ¼ 0.015) were independent predictors of MAACE. A multiparametric CMR weighted predictive derived score identifies subjects at high risk for MAACE compared with TTE-LVEF cutoff of 35% with a NRI of 31.7% (P ¼ 0.007).</p> <p><strong>CONCLUSIONS</strong> The DERIVATE-ICM registry is a large multicenter registry showing the additional value of CMR to stratify the risk for MAACE in a large cohort of patients with ICM compared with standard of care.</p>
Devitalized Non-valved Pulmonary Artery Allograft Implant for the Repair of Congenital Cardiac Abnormalities
ClinicalTrials.gov study NCT00411658. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Co-expression Networks of mRNAs and non-coding RNAs of bones around implants in hyperlipidemic rats (RNA-seq data sets)
GEO Series GSE113520. Rattus norvegicus. 8 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.
Transcriptomic of early embryonic invasion at implantation sites in a murine model.
GEO Series GSE46732. Mus musculus. 9 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.